CAV1 and malignant peripheral nerve sheath tumor: While the proteasomal inhibitor MG132 markedly increased CAV1 protein levels in a time-dependent manner (Fig. 2g) in CAV1 low expression cell line ST8814, indicating that CAV1 is mainly degraded via the proteasomal pathway in NF1-MPNST cells.